Synaffix Expands Partnership Horizon with Boehringer Ingelheim
January 9, 2025 - 17:10
In a significant move to enhance its portfolio, Synaffix, a leader in antibody-drug conjugate (ADC) technology, has entered into a new licensing agreement with Boehringer Ingelheim. This partnership allows Boehringer to leverage Synaffix's advanced ADC technologies for a specified number of cancer targets, although the exact details regarding the number of targets remain confidential.
This agreement marks a strategic step for Synaffix as it continues to build on its momentum from last year, when it secured several partnerships. Additionally, Synaffix has expanded its collaboration network by forming a technology licensing deal with Mitsubishi Tanabe Pharma in Japan. These developments underscore Synaffix's commitment to advancing cancer treatment options through innovative ADC technologies.
As the landscape of cancer therapeutics evolves, this collaboration with Boehringer Ingelheim is poised to accelerate the development of novel ADC therapies, potentially leading to more effective treatment solutions for patients battling cancer.
MORE NEWS
June 10, 2026 - 04:24
MIT SPURS looks to the future of urban technology and policyThe MIT Special Program for Urban and Regional Studies, known as SPURS, is undergoing a significant curriculum overhaul to center on technology policy and its intersection with urban development....
June 9, 2026 - 08:34
Arrow McLaren Finds Encouraging Signs in World Wide Technology Raceway Night RaceThe Arrow McLaren team left World Wide Technology Raceway with a mix of results but a clear sense of direction after a challenging night race. Driver Pato O`Ward fought hard through the field,...
June 8, 2026 - 20:56
Steve Rao: The AI revolution must include Main StreetSmall businesses are often left out of the conversation when it comes to technological revolutions. But as artificial intelligence reshapes the economy, the real test of its success will be whether...
June 8, 2026 - 04:08
Hivemind Capital Launches darkmatter lab With UC Berkeley To Accelerate Frontier Technology CommercializationHivemind Capital has announced the creation of darkmatter lab, a new initiative developed in collaboration with UC Berkeley aimed at pushing frontier technologies from the lab into the market...